Androgenetic alopecia — the most common form of hair thinning — is caused by the androgen hormone DHT (dihydrotestosterone) binding to receptors within the scalp hair follicle. Once bound, DHT triggers a cascade of signals that progressively shrinks the follicle over months and years — a process called follicular miniaturization.
Each successive growth cycle, the affected follicle produces a shorter, thinner hair shaft. Eventually, the follicle enters a permanent resting phase and stops producing visible hair entirely.
Published Clinical Evidence
Fischer et al., 2007 (International Journal of Dermatology): Topical caffeine applied directly to isolated human hair follicles in culture significantly stimulated hair shaft elongation and counteracted testosterone-induced growth suppression — extending the anagen phase by up to 46%.
Panahi et al., 2015 (Skinmed): A double-blind RCT in 100 patients compared rosemary oil to minoxidil 2% over 6 months. Both groups achieved statistically equivalent hair count improvement. The rosemary group reported significantly fewer adverse scalp events.
Patel et al., 2017 (Skin Appendage Disorders): Review of biotin supplementation in individuals with documented deficiency showed improvement in hair quality and tensile strength.
Rather than targeting a single mechanism, HaloGrow addresses four distinct biological pathways involved in healthy follicle function:
Oral DHT-blocking medications achieve systemic effect — meaning they affect DHT levels throughout the entire body. This creates a risk profile including hormonal side effects. HaloGrow's spray delivery confines its active compounds to the scalp tissue, where they are needed, without systemic absorption — eliminating these risks entirely.